Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action
Creators
- Charalampia Amerikanou1
- Efstathia Papada1
- Aristea Gioxari1
- Ilias Smyrnioudis2
- Stamatia-Angeliki Kleftaki1
- Evdokia Valsamidou1
- Victoria Bruns3
- Rajarshi Banerjee4
- Maria Giovanna Trivella5
- Natasa Milic6
- Milica Medić‐Stojanoska6
- Amalia Gastaldelli7
- Aimo Kannt8
- MAST4HEALTH1
- George V. Dedoussis1
- Andriana C. Kaliora1
- 1. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece
- 2. Chios Mastic Gum Growers Association, Chios, Greece
- 3. Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany
- 4. Perspectum Ltd, Oxford, UK
- 5. ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 6. Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
- 7. Institute of Clinical Physiology National Research Council, Pisa, Italy
- 8. Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Description
Mastiha is a natural nutritional supplement with known anti-inflammatory properties. Non-alcoholic fatty liver disease (NAFLD) and Inflammatory bowel disease (IBD) are immune mediated inflammatory diseases that share common pathophysiological features. Mastiha has shown beneficial effects in both diseases. MicroRNAs have emerged as key regulators of inflammation and their modulation by phytochemicals have been extensively studied over the last years. Therefore, the aim of this study was to investigate whether a common route exists in the anti-inflammatory activity of Mastiha, specifically through the regulation of miRNA levels. Plasma miR-16, miR-21 and miR-155 were measured by Real-Time PCR before and after two double blinded and placebo-controlled randomized clinical trials with Mastiha. In NAFLD, miR-155 decreased in the placebo group (p=0.054) whereas it remained unchanged in the Mastiha group. In all IBD and particulary in ulcerative colitis patients in relapse, miR-155 increased in the placebo group (p=0.054) whereas this increase was prevented by Mastiha. The mean changes were different in the two groups even after adjusting for age, sex and BMI (p=0.024 for IBD and p=0.042 for ulcerative colitis patients in relapse). Our results propose a regulatory role for Mastiha in circulating levels of miR-155, a critical player in T helper-17 (Th17) differentiation and function.
Files
Files
(454.1 kB)
Name | Size | Download all |
---|---|---|
md5:68ff394f16d08b4c8c491937a29755c6
|
454.1 kB | Download |